Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer

Lung cancer is the most commonly diagnosed cancer worldwide (excluding non-melanoma skin cancer), with 1.8 million new cases diagnosed in 2012. In addition, lung cancer gives the leading figure in mortality from oncological illnesses both in the United States and worldwide (1).